1. Pink Sheet

Will FDA GMP Observations Stall Biocon’s Run?

 
• By Anju Ghangurde

The FDA has flagged up GMP deviations at Biocon’s Bangalore site, though the company asserts that most of these are procedural blips resulting from ‘heightened’ regulatory expectations. The compliance concerns come ahead of the user fee goal date for Biocon and partner Mylan’s biosimilar trastuzumab next month.

SC1610_PillsMagnifyingGlass_1200x675

Biocon Ltd. continues to grapple with GMP challenges – this time an FDA audit has identified 10 deviations at its Bangalore manufacturing site, though the company suggests it is already on course to set things right. The FDA inspection at Biocon’s Bommasandra site in Bangalore was done between May 25 and June 3.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance